The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 May 3

PMID 28460462

Citations 41

Authors

Nora Ness

Sigve Andersen

Mehrdad Rakaee Khanehkenari

Cecilie V Nordbakken

Andrej Valkov

Erna-Elise Paulsen

Yngve Nordby

Roy M Bremnes

Tom Donnem

Lill-Tove Busund

Elin Richardsen

Affiliations

Soon will be listed here.

Abstract

Programmed cell death protein 1 (PD-1) and its ligand Programmed death ligand 1 (PD-L1) have gained massive attention in cancer research due to recent availability and their targeted antitumor effects. Their role in prostate cancer is still undetermined. We constructed tissue microarrays from prostatectomy specimens from 535 prostate cancer patients. Following validation of antibodies, immunohistochemistry was used to evaluate the expression of PD-1 in lymphocytes and PD-L1 in epithelial and stromal cells of primary tumors. PD-L1 expression was commonly seen in tumor epithelial cells (92% of cases). Univariate survival analysis revealed a positive association between a high density of PD-1+ lymphocytes and worse clinical failure-free survival, limited to a trend (p = 0.084). In subgroups known to indicate unfavorable prostate cancer prognosis (Gleason grade 9, age < 65, preoperative PSA > 10, pT3) patients with high density of PD-1+ lymphocytes had a significantly higher risk of clinical failure (p = < 0.001, p = 0.025, p = 0.039 and p = 0.011, respectively). In the multivariate analysis, high density of PD-1+ lymphocytes was a significant negative independent prognostic factor for clinical failure-free survival (HR = 2.48, CI 95% 1.12-5.48, p = 0.025).

Citing Articles

Long-term outcome and antitumor immune activation response in prostate cancer treated with low-dose-rate brachytherapy.

Wang Z, Wang L, Zhang Q, Xu Y, Zhang C Medicine (Baltimore). 2025; 103(47):e40574.

PMID: 39809175 PMC: 11596431. DOI: 10.1097/MD.0000000000040574.

Unveiling the molecular profile of a prostate carcinoma: implications for personalized medicine.

Agostini M, Giacobbi E, Servadei F, Bishof J, Funke L, Sica G Biol Direct. 2024; 19(1):146.

PMID: 39741346 PMC: 11686862. DOI: 10.1186/s13062-024-00492-z.

An immune suppressive tumor microenvironment in primary prostate cancer promotes tumor immune escape.

Anton A, Hutchinson R, Hovens C, Christie M, Ryan A, Gibbs P PLoS One. 2024; 19(11):e0301943.

PMID: 39602457 PMC: 11602054. DOI: 10.1371/journal.pone.0301943.

Evidence of Programmed Death-Ligand 1 Expression in a Highly Inflammatory Prostate: A Literature Review and Our Experience.

Koleva M, Mollova-Kyosebekirova A, Dikov D Cureus. 2024; 16(8):e67726.

PMID: 39318940 PMC: 11421409. DOI: 10.7759/cureus.67726.

Comprehensive Analysis of DNA Methyltransferases Expression in Primary and Relapsed Ovarian Carcinoma.

Papakonstantinou E, Pappa I, Androutsopoulos G, Adonakis G, Maroulis I, Tzelepi V Cancers (Basel). 2023; 15(20).

PMID: 37894317 PMC: 10605797. DOI: 10.3390/cancers15204950.

References

Baitsch L, Fuertes-Marraco S, Legat A, Meyer C, Speiser D . The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012; 33(7):364-72. DOI: 10.1016/j.it.2012.02.006. View

Ahmadzadeh M, Johnson L, Heemskerk B, Wunderlich J, Dudley M, White D . Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8):1537-44. PMC: 2927090. DOI: 10.1182/blood-2008-12-195792. View

Gridelli C, Besse B, Brahmer J, Crino L, Felip E, de Marinis F . The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2016; 17(3):161-8. DOI: 10.1016/j.cllc.2016.01.004. View

Massari F, Ciccarese C, Calio A, Munari E, Cima L, Porcaro A . Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. Target Oncol. 2015; 11(3):345-51. DOI: 10.1007/s11523-015-0396-3. View

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

Graff J, Alumkal J, Drake C, Thomas G, Redmond W, Farhad M . Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget. 2016; 7(33):52810-52817. PMC: 5288150. DOI: 10.18632/oncotarget.10547. View

Akbay E, Koyama S, Carretero J, Altabef A, Tchaicha J, Christensen C . Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013; 3(12):1355-63. PMC: 3864135. DOI: 10.1158/2159-8290.CD-13-0310. View

Ebelt K, Babaryka G, Frankenberger B, Stief C, Eisenmenger W, Kirchner T . Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur J Cancer. 2009; 45(9):1664-72. DOI: 10.1016/j.ejca.2009.02.015. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

10.

Drake C, Doody A, Mihalyo M, Huang C, Kelleher E, Ravi S . Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005; 7(3):239-49. PMC: 2846360. DOI: 10.1016/j.ccr.2005.01.027. View

11.

van der Kwast T, Roobol M . Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol. 2013; 10(8):473-82. DOI: 10.1038/nrurol.2013.112. View

12.

Davidsson S, Ohlson A, Andersson S, Fall K, Meisner A, Fiorentino M . CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol. 2012; 26(3):448-55. DOI: 10.1038/modpathol.2012.164. View

13.

Sunshine J, Taube J . PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015; 23:32-8. PMC: 4516625. DOI: 10.1016/j.coph.2015.05.011. View

14.

Andersen S, Richardsen E, Nordby Y, Ness N, Storkersen O, Al-Shibli K . Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol. 2014; 14:49. PMC: 4067377. DOI: 10.1186/1471-2490-14-49. View

15.

Zhu J, Chen L, Zou L, Yang P, Wu R, Mao Y . MiR-20b, -21, and -130b inhibit PTEN expression resulting in B7-H1 over-expression in advanced colorectal cancer. Hum Immunol. 2014; 75(4):348-53. DOI: 10.1016/j.humimm.2014.01.006. View

16.

Epstein J, Zelefsky M, Sjoberg D, Nelson J, Egevad L, Magi-Galluzzi C . A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2015; 69(3):428-35. PMC: 5002992. DOI: 10.1016/j.eururo.2015.06.046. View

17.

Concha-Benavente F, Srivastava R, Trivedi S, Lei Y, Chandran U, Seethala R . Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Res. 2015; 76(5):1031-43. PMC: 4775348. DOI: 10.1158/0008-5472.CAN-15-2001. View

18.

Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S . Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer. Prostate. 2014; 74(14):1452-61. DOI: 10.1002/pros.22862. View

19.

Martin A, Nirschl T, Nirschl C, Francica B, Kochel C, van Bokhoven A . Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015; 18(4):325-32. PMC: 4641011. DOI: 10.1038/pcan.2015.39. View

20.

Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S . High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer. 2012; 49(6):1273-9. DOI: 10.1016/j.ejca.2012.11.035. View